Anubhuti Mishra, equity research analyst at Swastika Investmart also said, "The upcoming listing of Concord Biotech is expected to be at a premium of around Rs 122 (16.46 percent) per share. This would mean that the shares could list at a price of around Rs 863 per share."Read more at:
